Milprazon 12.5mg/125mg for Dogs

Description

Milprazon Chewable 12.5 mg/125 mg delivers a dual-active formulation combining milbemycin oxime and praziquantel in a single oral dose. Each film-coated tablet addresses both cestode and nematode infections simultaneously, eliminating the need for separate anthelmintic courses. Dogs weighing below 5 kg should not receive this tablet; a lower-strength variant applies to that weight range.

Recommended for: Dogs weighing 5 kg to 25 kg (approximately 11 lbs to 55 lbs).

Indication/Coverage

For dogs with, or at risk of, multiple parasitic infections, Milprazon 12.5mg/125mg is indicated for the following conditions:

• Dipylidium caninum (tapeworm): Treatment of adult cestode infection; concurrent flea and lice control is recommended to interrupt the parasite’s lifecycle and prevent re-infestation.
• Taenia spp. (tapeworm): Treatment of adult cestode infection in the gastrointestinal tract.
• Echinococcus spp. (hydatid tapeworm): Treatment of adult cestode infection; this genus is zoonotic and notifiable to WOAH, requiring local regulatory guidance for follow-up protocols.
• Mesocestoides spp. (tapeworm): Treatment of adult cestode infection.
• Ancylostoma caninum (hookworm): Treatment of adult nematode infection causing intestinal blood loss, particularly in young or debilitated dogs.
• Toxocara canis (roundworm): Treatment of adult nematode infection; zoonotic potential warrants attention in households with children.
• Toxascaris leonina (roundworm): Treatment of adult nematode infection of the gastrointestinal tract.
• Trichuris vulpis (whipworm): Treatment of adult nematode infection causing large intestinal inflammation.
• Crenosoma vulpis (fox lungworm): Reduction of infection burden; does not achieve complete elimination at a single standard dose.
• Angiostrongylus vasorum (French heartworm): Reduction of immature adult (L5) and adult parasite burden. Milbemycin oxime should be given four times at weekly intervals. Use Milprazon for the first weekly dose, then use a milbemycin oxime-only product for the next 3 weekly doses if tapeworm treatment is also needed. In endemic areas where concurrent tapeworm treatment is required, monthly dosing with Milprazon reduces ongoing parasite burden.
• Thelazia callipaeda (eyeworm): Treatment requires two milbemycin oxime administrations seven days apart. Where concomitant tapeworm treatment is indicated, Milprazon can replace the monovalent milbemycin oxime product for this schedule.
• Dirofilaria immitis (heartworm, prevention only): Monthly dosing prevents establishment of larval heartworm when concomitant tapeworm treatment is indicated; this product is not a stand-alone heartworm preventive and is not labeled for adulticidal therapy.

Key Benefits

The following benefits reflect the labeled pharmacological properties and approved indications for Milprazon Chewable 12.5 mg/125 mg:

• Dual-active formulation: Milbemycin oxime targets nematodes and heartworm larvae; praziquantel addresses cestodes. A single dose covers both parasite classes without requiring two separate products.
• Minimum weight eligibility: Labeled for dogs from 5 kg, this tablet delivers milbemycin oxime at a minimum of 0.5 mg/kg and praziquantel at 5 mg/kg. Dogs below 5 kg fall outside the approved dosing range and should not receive this formulation.
• Heartworm prevention with concurrent tapeworm coverage: Monthly administration prevents Dirofilaria immitis larval development in dogs residing in or traveling through heartworm-endemic regions, while also clearing tapeworm burden in a single treatment cycle.
• Dual mechanism of action: Milbemycin oxime increases nematode membrane permeability to chloride ions via glutamate-gated chloride channels, producing flaccid paralysis and death of the parasite. Praziquantel disrupts calcium ion permeability in cestode membranes, triggering rapid muscular contraction and tegumental disintegration.
• Palatable tablet format: Voluntary acceptance was observed in over 80% of dogs in studies, which reduces handling stress during administration. Dogs that decline to take the tablet voluntarily can receive it by direct oral placement.
• Efficacy across multiple life stages: Coverage extends to immature adult (L5) and adult stages of Angiostrongylus vasorum, and larval stages of Dirofilaria immitis, not only patent adult infections.
• Safe during pregnancy and lactation: The formulation is approved for use in breeding, pregnant, and lactating dogs, making it suitable across the full reproductive cycle without requiring dose interruption.
• Established oral absorption profile: Milbemycin oxime reaches peak plasma levels within 0.75 to 3.5 hours after administration with food. Bioavailability is approximately 80%, ensuring consistent systemic exposure at each monthly dose.

Caution

Hazards to Humans

Accidental ingestion by a child may be harmful; if this occurs, seek medical advice immediately and show the package leaflet to the physician. Administer and store tablets out of sight and reach of children, as the flavored formulation may attract unsupervised handling. Wash hands after use.

Hazards to Domestic Animals

Milprazon Chewable 12.5 mg/125 mg is for oral use only; do not administer to dogs weighing less than 5 kg or younger than 4 weeks. Dogs of Collie or related breeds have a narrower margin of safety with milbemycin oxime, and the labeled dose should be observed precisely. Use in dogs with microfilaremia is not recommended, as die-off reactions from circulating microfilariae can produce hypersensitivity responses including pale mucous membranes, vomiting, and labored breathing. Dogs with severely compromised kidney or liver function, or in debilitated condition, should only receive this product following a veterinary benefit-risk assessment. Caution is warranted when co-administering with other macrocyclic lactones, as interaction studies beyond selamectin are not available.

Possible Side Effects

Monitor your dog after each administration, particularly following the first dose. The adverse reactions documented for Milprazon Chewable 12.5 mg/125 mg are classified as very rare, occurring in fewer than 1 in 10,000 treated animals:

• Hypersensitivity reactions: These may present acutely following administration, particularly in dogs with high circulating microfilariae load. Signs include pale mucous membranes, labored breathing, and excessive salivation.
• Gastrointestinal signs: Vomiting, diarrhea, anorexia, and drooling have been reported at this frequency. Administering the tablet with food reduces the likelihood of GI intolerance.
• Systemic signs: Lethargy and neurological disturbances including muscle tremors and ataxia fall within the very rare classification. These signs are consistent with milbemycin oxime overdose effects in Collie-type breeds when the dose is not precisely observed.

If any of these signs emerge, discontinue dosing and consult a veterinarian before the next scheduled administration.